Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 247

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The concept of treatment-free remission in chronic myeloid leukemia

Open access
Saußele, S, Richter, J, Hochhaus, A, Mahon, F-X · 2016 · Leukemia

Abstract

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is approaching that of the general population but lifelong treatment is still recommended. In several trials, TKI treatment has been stopped successfully in approximately half of the patients with deep molecular response. This has prompted the development of a new concept in the evaluation of CML patients known as 'treatment-free remission'. The future in CML treatment will be to define criteria for the safe and most promising discontinuation of TKI on one hand, and, on the other, to increase the number of patients available for such an attempt. Until safe criteria have been defined, discontinuation of therapy is still experimental and should be restricted to clinical trials or registries. This review will provide an overview of current knowledge as well as an outlook on future challenges.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2016.115

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 76

  1. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553–561. · DOI · Paper page
  2. Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J et al. Success Story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514–2520. · DOI · Paper page
  3. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415–423. · DOI · Paper page
  4. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 29: 1823–1831. · DOI
  5. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884. · DOI · Paper page
  6. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118: 4554–4560. · DOI · Paper page
  7. Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in cml over a period of 10 years: data from the randomized cml-study iv. Leukemia 2015; 29: 1123–1132. · DOI · Paper page
  8. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783–1796. · DOI · Paper page
  9. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27: 1316–1321. · DOI · Paper page
  10. Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013; 27: 1511–1519. · DOI
  11. Efficace F, Breccia M, Saussele S, Kossak U, Caocci G, Sprangers M et al. International development of an EORTC measure to assess patient-reported quality of life (QoL) and symptoms in chronic myeloid leukemia (CML). Blood 2011; 118: 1353–1354. · DOI · Paper page
  12. Lütge I, Pfirrmann M, Stalljann I, Illmer T, Schafhausen P, Kiani A et al. Health-related quality of life in CML patients under nilotinib firts-line treatment: Results of a German sub-study within the ENEST 1st trial. Hamatologica 2015; 100, Abstract P233. · doi:10.3324/haematol.2014.120089
  13. Hochhaus A . Educational session: managing chronic myeloid leukemia as a chronic disease. Hematology Am Soc Hematol Educ Program 2011; 2011: 128–135. · DOI
  14. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175. · DOI · Paper page
  15. Cross NC, Hochhaus A, Müller MC . Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 2015; 94: S219–S225. · DOI
  16. Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, Barthe C et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002; 20: 214–220. · doi:10.1200/jco.2002.20.1.214
  17. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033–1041. · doi:10.1002/cncr.11223
  18. Cortes J, O'Brien S, Kantarjian H . To the editor: discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205. · DOI · Paper page
  19. Mauro MJ, Druker BJ, Maziarz RT . Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28: S71–S73. · DOI
  20. Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M . Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 979–981.
  21. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60. · DOI · Paper page
  22. Mahon FX . Is going for cure in chronic myeloid leukemia possible and justifiable? Hematology Am Soc Hematol Educ Program 2012; 2012: 122–128. · DOI
  23. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035. · DOI · Paper page
  24. Etienne G, Rea D, Guilhot J, Guilhot F, Huguet F, Legros L et al Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients. ASH Annual Meeting Abstracts 2015: Abstract No. 345. · doi:10.1182/blood.v126.23.345.345
  25. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515–522. · DOI · Paper page
  26. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 24: 1719–1724. · DOI · Paper page
  27. Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013; 121: 3818–3824. · DOI · Paper page
  28. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012; 97: 903–906. · DOI
  29. Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 2015; 90: 910–914. · DOI · Paper page
  30. Nicolini FE, Noël M-P, Escoffre M, Charbonnier A, Rea D, Dubruille V et al. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood 2013; 122: Abstract 654. · DOI
  31. Saussele S, Richter J, Guilhot J, Müller M, Dietz C, Porkka K et al. First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial.19th Congress of the European Hematology Association, Milan, Italy, June 12-15, 2014. Haematologica 2014; 99: 792; Abstract LB2440.
  32. Rea D, Rousselot P, Guilhot F, Tulliez M, Nicolini FE, Guerci-Bresler A et al Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. ASH Annual Meeting Abstracts 2012; 120: 916. · DOI
  33. Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015; 2: e528–e535. · DOI · Paper page
  34. Mahon FX, Baccarani M, Mauro MJ, Hughes TP, Saglio G, Savona M et al. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. J Clin Oncol 2014; 32: abstract TPS7124. · doi:10.1200/jco.2014.32.15_suppl.tps7124
  35. Esteve J, Benhamou E, Raymond L . Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ 1994; IV: 1–302.
  36. Mahon FX, Richter J, Guilhot J, Muller MC, Dietz C, Porkka K et al. Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: The EURO-SKI study. Blood 2014; 124: 151. · DOI
  37. Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM et al. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 2011; 17: 6812–6821. · DOI
  38. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M . Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181–1184. · DOI · Paper page
  39. Horn M, Glauche I, Muller MC, Hehlmann R, Hochhaus A, Loeffler M et al. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 2013; 121: 378–384. · DOI
  40. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37. · DOI · Paper page
  41. Saussele S, Stein M, Gil A, Kossak-Roth U, Lauseker M, Proetel U et al Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials. ASH Annual Meeting Abstracts 2015: Abstract No. 2773. · doi:10.1182/blood.v126.23.2773.2773
  42. Goldberg S, Hamarman S . Patients with Chronic Myelogenous Leukemia May Not Want to Discontinue Tyrosine Kinase Inhibitor Therapy. ASH Annual Meeting Abstracts 2015: Abstract No. 1584. · doi:10.1182/blood.v126.23.1584.1584
  43. Experts in Chronic Myeloid L. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439–4442. · DOI · Paper page
  44. Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 2014; 32: 2821–2823. · DOI
  45. Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ et al. Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma 2016; 57: 341–347. · DOI
  46. Berger MG, Pereira P, Oris C, Saugues S, Cony-Makhoul P, Gardembas M et al Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort. ASH Annual Meeting Abstracts 2015: Abstract No. 137. · doi:10.1182/blood.v126.23.137.137
  47. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145. · DOI · Paper page
  48. Galimberti S, Fontanelli G, Barsotti S, Ricci F, Guerrini F, Ciabatti E et al. PDGFRB sustains the "withdrawal syndrome" after imatinib discontinuation. haematologica 2015; 100: 697 (abstract PB1759).
  49. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501–1510. · DOI · Paper page
  50. Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657–3660. · DOI · Paper page
  51. Holyoake TL, Helgason GV . Do we need more drugs for chronic myeloid leukemia? Immunol Rev 2015; 263: 106–123. · DOI
  52. Talpaz M, Mercer J, Hehlmann R . The interferon-alpha revival in CML. Ann Hematol 2015; 94: S195–S207. · DOI
  53. Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 2010; 5: e11770. · DOI
  54. Burchert A, Saussele S, Eigendorff E, Muller MC, Sohlbach K, Inselmann S et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia 2015; 29: 1331–1335. · DOI
  55. Ilander MM, Olsson-Strömberg U, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S et al. Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI. Blood (ASH Annual Meeting Abstracts). 2013; 122: abstract 379. · doi:10.1182/blood.v122.21.379.379
  56. Hughes A, Tang C, Clarson J, Vidovic L, Hughes TP, Yong AS . Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors. Blood (ASH Annual Meeting Abstracts). 2015; 126: abstract no. 18. · doi:10.1182/blood.v126.23.18.18
  57. Ilander M, Schlums H, Olsson-Strömberg U, Lähteenmäki H, Kasanen T, Koskenvesa P et alMature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. Blood (ASH Annual Meeting Abstracts) 2015; 126: abstract no. 343. · doi:10.1182/blood.v126.23.343.343
  58. Burchert A, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E et al. Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial. Blood (ASH Annual Meeting Abstracts). 2015; 126: abstract no. 599. · doi:10.1182/blood.v126.23.599.599
  59. Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S et al. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Exp Hematol 2015; 43: 1015–1018. · DOI
  60. Yeung DT, Vidovic L, Tang C, White DL, Branford S, Hughes TP et al. KIR2DL5B genotype independently predicts poor outcomes in CML-CP patients switched to nilotinib after suboptimal responses to imatinib and may refine prognosis in patients with EMR failure. Blood 2014; 124: 814–814. · DOI
  61. Copland M . Chronic myelogenous leukemia stem cells: what's new? Curr Hematol Malig Rep 2009; 4: 66–73. · DOI
  62. Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 2015; 525: 380–383. · DOI · Paper page
  63. Deininger MW . Molecular monitoring in CML and the prospects for treatment-free remissions. Hematology Am Soc Hematol Educ Program 2015; 2015: 257–263. · DOI
  64. Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957–1963. · DOI · Paper page
  65. Melo JV, Ross DM . Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematology Am Soc Hematol Educ Program 2011; 2011: 136–142. · DOI
  66. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367. · DOI · Paper page
  67. Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A . Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119: 530–539. · DOI
  68. Deininger M . Hematology: curing CML with imatinib—a dream come true? Nat Rev Clin Oncol 2011; 8: 127–128. · doi:10.1038/nrclinonc.2011.17
  69. Falchi L, Kantarjian HM, Wang X, Verma D, Quintas-Cardama A, O'Brien S et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 2013; 88: 1024–1029. · DOI
  70. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054. · DOI · Paper page
  71. Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2015; 30: 57–64. · DOI
  72. 14. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu?? C et al. Final 5-year study results of DASISION: the DASatinib versus imatinib study in treatment-naive CML patients trial. J Clin Oncol 2016 · DOI · Paper page
  73. Larson RA . Is there a best TKI for chronic phase CML? Blood 2015; 126: 2370–2375. · doi:10.1182/blood-2015-06-641043
  74. Palani R, Milojkovic D, Apperley JF . Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 2015; 94: S167–S176. · DOI
  75. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M . Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 2016; 127: 392–399. · DOI · Paper page
  76. Cross NC . Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 355–365. · DOI

Cited by

See all 247

Metadata

Authors
Saußele, S., Richter, J., Hochhaus, A., & Mahon, F.-X.
Venue
Leukemia
Published
2016-05-02
Volume
30
Issue
8
Pages
1638-1647
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2345930365
Cited by
247
References
4
FWCI
37.66
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-sa/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.